As demand rises and budgets constrain across the continent reimbursement for Oncology drugs has become a significant challenge for European pharma. What has become clear is that developing market access on a country-by-country basis is key. We've commissioned this paper to analyse how Germany, UK and Spain have developed as this will prove an effective benchmark for other EU countries to springboard their models from.
The paper will cover:
An extract from the piece:
“It is crucial to begin the process of engaging payers early to understand their requirements. Starting this process after the drug is already in phase III is not recommended as you have missed the optimum opportunity to gain data which will meet payer requirements.”